ArticleClinical pharmacology in drug development2022

Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors.

Shringi Sharma et al.PubMed ↗Publisher ↗

No numbers read from the abstract.